335 related articles for article (PubMed ID: 26246472)
1. Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.
Liu X; Chen X; Rycaj K; Chao HP; Deng Q; Jeter C; Liu C; Honorio S; Li H; Davis T; Suraneni M; Laffin B; Qin J; Li Q; Yang T; Whitney P; Shen J; Huang J; Tang DG
Oncotarget; 2015 Sep; 6(27):23959-86. PubMed ID: 26246472
[TBL] [Abstract][Full Text] [Related]
2. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.
Qin J; Liu X; Laffin B; Chen X; Choy G; Jeter CR; Calhoun-Davis T; Li H; Palapattu GS; Pang S; Lin K; Huang J; Ivanov I; Li W; Suraneni MV; Tang DG
Cell Stem Cell; 2012 May; 10(5):556-69. PubMed ID: 22560078
[TBL] [Abstract][Full Text] [Related]
3. Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.
Chen X; Li Q; Liu X; Liu C; Liu R; Rycaj K; Zhang D; Liu B; Jeter C; Calhoun-Davis T; Lin K; Lu Y; Chao HP; Shen J; Tang DG
Clin Cancer Res; 2016 Sep; 22(17):4505-16. PubMed ID: 27060154
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.
Rycaj K; Cho EJ; Liu X; Chao HP; Liu B; Li Q; Devkota AK; Zhang D; Chen X; Moore J; Dalby KN; Tang DG
Oncotarget; 2016 Mar; 7(12):14220-40. PubMed ID: 26871947
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
Jamroze A; Chatta G; Tang DG
Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
[TBL] [Abstract][Full Text] [Related]
7. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
8. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
9. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells.
Patrawala L; Calhoun-Davis T; Schneider-Broussard R; Tang DG
Cancer Res; 2007 Jul; 67(14):6796-805. PubMed ID: 17638891
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
11. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
12. Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
Zhang J; Li Q; Zhang S; Xu Q; Wang T
Exp Cell Res; 2016 Nov; 349(1):77-84. PubMed ID: 27743893
[TBL] [Abstract][Full Text] [Related]
13. Phage display screening identifies a prostate specific antigen (PSA)
Sui Y; Zhu R; Hu W; Zhang W; Zhu H; Gong M; Gao L; Cao T; Tang T; Yu B; Yang T
Transl Oncol; 2021 Mar; 14(3):101020. PubMed ID: 33508757
[TBL] [Abstract][Full Text] [Related]
14. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.
Liu R; Liu C; Zhang D; Liu B; Chen X; Rycaj K; Jeter C; Calhoun-Davis T; Li Y; Yang T; Wang J; Tang DG
Oncotarget; 2016 Aug; 7(35):56628-56642. PubMed ID: 27447749
[TBL] [Abstract][Full Text] [Related]
15. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
16. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer.
Sarwar M; Sandberg S; Abrahamsson PA; Persson JL
Urol Oncol; 2014 Jan; 32(1):25.e1-12. PubMed ID: 23410945
[TBL] [Abstract][Full Text] [Related]
18. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription.
Liu Y; Liu Y; Yuan B; Yin L; Peng Y; Yu X; Zhou W; Gong Z; Liu J; He L; Li X
Oncotarget; 2017 Mar; 8(10):17027-17037. PubMed ID: 28199985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
